SGSuqin Guo

Suqin Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Suqin Guo has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Comparative Analysis and Phylogenetic Relationship of the Chloroplast Genome Sequences of Illicium verum and Illicium difengpi

    by Suqin Guo, Xiqun Wu, Feng Peng, Kun Zhang, Suren Rao Sooranna, Guiyu Tan

    Background/Objectives: Illicium verum Hook. f. and Illicium difengpi K. I. B.et K. I. M. are two important medicinal plants which grow in the mountainous areas of Guangxi, China. Their similar morphological characteristics frequently lead to their misidentification. Chloroplast genome (cp)-based barcode technology has been used to effectively identify two closely related species; however, at present, there is no systematic comparative study of the cp genome sequences between I. verum and I. difengpi. Methods: Here, the cp genomes of the two plants were sequenced and analyzed. Results: The cp genome sizes were 142,689 and 142,689 bp for I. verum and I. difengpi, respectively. Each of the cp genomes annotated 122 genes, with 79 protein coding genes, 8 ribosomal RNA genes, and 35 transfer RNA genes. Amino acid frequencies of 1.17–10.19% (I. verum) and 1.18–10.17% (I. difengpi) were found in the coding genes. There were also 104 and 96 SSRs as well as 26 and 25 long repeats identified in I. verum and I. difengpi, respectively, among which the most common were A/T base repeats. Both cp genomes had SSC/IRa junctions located in gene ycf1-trnN. The ycf1 and trnL-trnV-rps7 genes were positioned at the IRb/SSC and LSC/IR boundaries, respectively. A phylogenetic relationship was constructed and the two species were fully nested within the genus Illicium. Conclusions: The comparative cp genomes of I. verum and I. difengpi are presented in this study, and this provides valuable phylogenetic information for subsequent molecular marker development and research of I. verum and I. difengpi.


  • Comparison of single-chain variable fragments and monoclonal antibody against dihydroartemisinin

    by Fang Lu, Xiqun Wu, Fa Zhang, Jiaqiang Wu, Zhaodong Yuan, Baomin Wang, Guiyu Tan, Suqin Guo


  • Preparation and application of a specific single-chain variable fragment against artemether

    by Fang Lu, Fa Zhang, Jingqi Qian, Tingting Huang, Liping Chen, Yilin Huang, Baomin Wang, Liwang Cui, Suqin Guo


  • Quality Testing of Artemisinin-Based Antimalarial Drugs in Myanmar

    by Suqin Guo, Myat Phone Kyaw, Lishan He, Myo Min, Xiangxue Ning, Wei Zhang, Baomin Wang, Liwang Cui

    Artemisinin-based combination therapies are the frontline treatment of Plasmodium falciparum malaria. The circulation of falsified and substandard artemisinin-based antimalarials in Southeast Asia has been a major predicament for the malaria elimination campaign. To provide an update of this situation, we purchased 153 artemisinin-containing antimalarials, as convenience samples, in private drug stores from different regions of Myanmar. The quality of these drugs in terms of their artemisinin derivative content was tested using specific dipsticks for these artemisinin derivatives, as point-of-care devices. A subset of these samples was further tested by high-performance liquid chromatography (HPLC). This survey identified that > 35% of the collected drugs were oral artesunate and artemether monotherapies. When tested with the dipsticks, all but one sample passed the assays, indicating that the detected artemisinin derivative content corresponded approximately to the labeled contents. However, one artesunate injection sample was found to contain no active ingredient at all by the dipstick assay and subsequent HPLC analysis. The continued circulation of oral monotherapies and the description, for the first time, of falsified parenteral artesunate provides a worrisome picture of the antimalarial drug quality in Myanmar during the malaria elimination phase, a situation that deserves more oversight from regulatory authorities.


  • Open Access

    Pilot testing of dipsticks as point-of-care assays for rapid diagnosis of poor-quality artemisinin drugs in endemic settings

    by Suqin Guo, Lishan He, Daniel J. Tisch, James Kazura, Sungano Mharakurwa, Jagadish Mahanta, Sócrates Herrera, Baomin Wang, Liwang Cui

    Good-quality artemisinin drugs are essential for malaria treatment, but increasing prevalence of poor-quality artemisinin drugs in many endemic countries hinders effective management of malaria cases. To develop a point-of-care assay for rapid identification of counterfeit and substandard artemisinin drugs for resource-limited areas, we used specific monoclonal antibodies against artesunate and artemether, and developed prototypes of lateral flow dipstick assays. In this pilot test, we evaluated the feasibility of these dipsticks under different endemic settings and their performance in the hands of untrained personnel. The results showed that the dipstick tests can be successfully performed by different investigators with the included instruction sheet. None of the artemether and artesunate drugs collected from public pharmacies in different endemic countries failed the test. It is possible that the simple dipstick assays, with future optimization of test conditions and sensitivity, can be used as a qualitative and semi-quantitative assay for rapid screening of counterfeit artemisinin drugs in endemic settings.


  • Open Access

    Development of a colloidal gold-based lateral flow dipstick immunoassay for rapid qualitative and semi-quantitative analysis of artesunate and dihydroartemisinin

    by Lishan He, Tiegui Nan, Yongliang Cui, Suqin Guo, Wei Zhang, Rui Zhang, Guiyu Tan, Baomin Wang, Liwang Cui

    Artemisinin-based combination therapy (ACT) plays an indispensable role in malaria control and elimination. However, the circulation of counterfeit, substandard drugs has greatly threatened malaria elimination campaigns. Most methods for the analysis of artemisinin and its derivatives require expensive equipment and sophisticated instrumentation. A convenient, easy-to-use diagnostic device for rapid evaluation of the quality of artemisinin drugs at the point-of-care is still lacking. In this study a lateral flow dipstick immunoassay was developed for qualitative and semi-quantitative analysis of artesunate (ATS) and dihydroartemisinin (DHA) in anti-malarial drugs. This assay was based on a monoclonal antibody (mAb) raised against ATS. ATS-bovine serum albumin and goat anti-mouse IgG, used as the test capture reagent and the control capture reagent, were coated on the nitrocellulose membrane to form the test line and control line, respectively. The conjugate pad was saturated with the gold-labelled anti-ATS mAb. The indicator range of the dipsticks, defined as lowest concentration of the target analytes between which the test line was not visible, were 100-200 and 200-500 ng mL-1 for ATS and DHA, respectively. No competitive inhibition was observed up to 5,000 ng mL-1 of quinine, chloroquine diphosphate salt, primaquine phosphate, pyrimethamine, lumefantrine, amodiaquine, piperaquine tetraphosphate tetrahydrate or pyronaridine tetraphosphate. Semi-quantitative analysis of ATS and DHA in commercial drugs and raw drug materials with the dipsticks produced result agreeable with those determined by high performance liquid chromatography (HPLC). Storage test showed that the indicator range for artemisinins remained unchanged after a week at 37°C and increased four-folds after six months of storage at 4°C or ambient temperature. The new selected mAb 3D82G7 with high avidity and broad cross reactivity for artemisinins was used to develop and optimize a dipstick immunoassay for qualitative and semi-quantitative analysis of ATS and DHA in anti-malarial drugs. The semi-quantitative analysis of ATS and DHA in commercial drugs and raw drug materials, and the specificity test of the artemisinin-related drugs both proved the accurate performance of the developed dipsticks for semi-quantitation of ACT samples. The dipstick may be used as a point-of-care device for identifying substandard and counterfeit ATS- and DHA-containing anti-malarial drugs.